Cherington Charles's Form 4 filing
Ernexa Therapeutics Inc. (ERNA) · filed Aug 25, 2023
- Accession no.
- 0001104659-23-095434
- Filed
- Aug 25, 2023, 7:34 PM ET
- Trade date
- Jul 13, 2023
- Filing delay
- 43 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 derivative transactions. It was filed 43 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cherington CharlesCIK 0001448698 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 13, 2023 | Common Stock | PPurchaseAcquired | +1,153,846 | $3,300,000.00 | – | – | Direct | Price outlier |
| Jul 13, 2023 | Common Stock | PPurchaseAcquired | +2,307,692 | $0.125F1 | +$288,461.5 | 2,307,692 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules.
Referenced by the price of 1 transaction in Table II.